Publication Name	World Journal of Respirology
Manuscript ID	4741
Country	Japan

Received	2013-07-20 09:18
Peer-Review Started	2013-07-22 19:22
To Make the First Decision	2013-08-08 11:32
Return for Revision	2013-08-16 19:57
Revised	2013-09-12 19:57
Second Decision	2013-10-11 14:57
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-10-12 00:37
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-10-18 17:18
Typeset the Manuscript	2013-10-29 16:35
Publish the Manuscript Online	2013-12-03 15:44

ISSN	2218-6255 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Autobiography
Article Title	Long-term survival of more than 3 years among patients with advanced non-small cell lung cancer treated with chemotherapy
Manuscript Source	Invited Manuscript
All Author List	Rieko Kaira, Kyoichi Kaira, Takehito Shukuya, Hirotsugu Kenmotsu, Akira Ono, Haruyasu Murakami, Asuka Tsuya, Yukiko Nakamura, Tateaki Naito, Masahiro Endo, Nobuyuki Yamamoto and Toshiaki Takahashi
Funding Agency and Grant Number
Corresponding Author	Kyoichi Kaira, MD, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. kkaira1970@yahoo.co.jp
Key Words	Non-small cell lung cancer; Long-term survivor; Chemotherapy; Performance status; Epidermal growth factor receptor-tyrosine kinase inhibitors
Core Tip	The aim of this study is to evaluate the prognostic factors of long-term survival of more than 3 years in advanced non-small cell lung cancer. Female sex, good performance status (PS), non-smoker and adenocarcinoma were significantly associated with long-term survivors of more than 3 years and most patients received epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) at any line treatment. PS of 0 was an independent prognostic factor for predicting favorable prognosis in the long-term survivors of more than 3 years. PS of 0, adenocarcinoma and EGFR-TKI therapy play an important role in the long-term survivors.
Publish Date	2013-12-03 15:44
Citation	Kaira R, Kaira K, Shukuya T, Kenmotsu H, Ono A, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Yamamoto N, Takahashi T. Long-term survival of more than 3 years among patients with advanced non-small cell lung cancer treated with chemotherapy. World J Respirol 2013; 3(3): 110-115
URL	http://www.wjgnet.com/2218-6255/full/v3/i3/110.htm
DOI	http://dx.doi.org/10.5320/wjr.v3.i3.110

Full Article (PDF)	WJR-3-110.pdf
Manuscript File	4741-Review.docx
Answering Reviewers	4741-Answering reviewers.pdf
Copyright License Agreement	4741-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	4741-Language certificate.docx
Peer-review Report	4741-Peer review(s).pdf
Scientific Editor Work List	4741-Scientific editor work list.doc